Supemtek®

Phase 3

Sanofi (SNY)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Morbid Obesity

View Full Landscape

Drug Information

Target Indication

Morbid Obesity

Clinical Trial

NCT05409612

Last updated: 8/22/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA3/30/2026

Supemtek

Supemtek is indicated for active immunisation for the prevention of influenza disease in adults and children from 9 years of age and older. Supemtek should be used in accordance with official recommendations.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

SNY

Sanofi

Pharmaceutical Preparations•Europe•NASDAQ

Related Pipeline

5-Fluoro-3-Pyridinecarboxylic AcidPhase 3

Larynx Cancer

Clopidogrel-aspirinPhase 3

Brain Infarction

Synvisc (Hylan G-F20; hyaluronan injection)Phase 3

Osteoarthritis

consolidation chemotherapy with Docetaxel plus cisplatinPhase 3

Carcinoma, Non-Small-Cell Lung

Epirubicin, cyclophosphamide and docetaxelPhase 3

Breast Neoplasms

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts